• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $REXN

    Rexahn Pharmaceuticals, Inc.

    Subscribe to $REXN
    $REXN
    Major Pharmaceuticals
    Health Care

    IPO Year: n/a

    Exchange: NASDAQ

    Recent Analyst Ratings for Rexahn Pharmaceuticals, Inc.

    DatePrice TargetRatingAnalyst
    See more ratings

    Rexahn Pharmaceuticals, Inc. Press Releases

    Fastest customizable press release news feed in the world

    View All

    MaxCyte Appoints Douglas Swirsky as Chief Financial Officer

    ROCKVILLE, Md., March 27, 2023 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ:MXCT, LSE: MXCT))), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics and to support innovative, cell-based research, today announced Douglas J. Swirsky has been appointed as the Company's Chief Financial Officer, effective immediately. Mr. Swirsky is a seasoned financial leader with over two decades of experience in the healthcare sector, including as a public company executive at Nasdaq-listed organizations. "We are excited to welcome Douglas to MaxCyte where he brings exceptio

    3/27/23 4:05:00 PM ET
    $CLRB
    $MXCT
    $REXN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Commercial Physical & Biological Resarch
    Major Pharmaceuticals

    Rexahn Pharmaceuticals, Inc. Leadership Updates

    Live Leadership Updates

    View All

    MaxCyte Appoints Douglas Swirsky as Chief Financial Officer

    ROCKVILLE, Md., March 27, 2023 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ:MXCT, LSE: MXCT))), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics and to support innovative, cell-based research, today announced Douglas J. Swirsky has been appointed as the Company's Chief Financial Officer, effective immediately. Mr. Swirsky is a seasoned financial leader with over two decades of experience in the healthcare sector, including as a public company executive at Nasdaq-listed organizations. "We are excited to welcome Douglas to MaxCyte where he brings exceptio

    3/27/23 4:05:00 PM ET
    $CLRB
    $MXCT
    $REXN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Commercial Physical & Biological Resarch
    Major Pharmaceuticals